The use of ANAM to assess the side-effect profiles and efficacy of medication.
Cognition has become increasingly important as an outcome measure in studies of medication. Traditional neuropsychological assessment is limited in its ability to detect subtle, medication-related changes and it is not suitable for the rapid serial assessment required in most clinical trials. Thus, investigators have turned to computerized neuropsychological assessment for its repeatability, sensitivity to subtle cognitive changes, and ease of administration. The automated neuropsychological assessment metrics (ANAM) is one such computerized battery that has been used to measure the effects of numerous CNS-active drugs. This paper is an exhaustive review of studies that have used ANAM to measure cognitive changes associated with pharmacological treatments. The benefits and limitations of using ANAM in clinical trials are discussed.
Wilken
Jeffrey A
JA
Veterans Affairs Medical Center, University of Maryland, College Park, Washington, DC, United States. jeffwilken1@aol.com
Sullivan
Cynthia L
CL
Lewandowski
Alan
A
Kane
Robert L
RL
D001921:Brain / Q000187:drug effects; D002491:Central Nervous System Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D003936:Diagnosis, Computer-Assisted; D006801:Humans; D009483:Neuropsychological Tests; D012016:Reference Values; D015203:Reproducibility of Results; D012984:Software
D002491:Central Nervous System Agents